Respected Sir/Madam, We have attached herewith Financial Results for the quarter ended on June 30, 2025. Kindly take the same on your record. Thank you.
AHCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 2.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anlon Healthcare, a Rajkot-based manufacturer of Active Pharmaceutical Ingredients (APIs) and drug intermediates, reported Q1 FY26 standalone results. Revenue from operations stood at Rs. 3,329.72 lacs, down about 12% from Rs. 3,783.25 lacs in the same quarter last year. Total income for the quarter was Rs. 3,330.89 lacs versus Rs. 3,789.34 lacs earlier. Profit before tax came in at Rs. 500.41 lacs (vs Rs. 552.51 lacs), while profit after tax was Rs. 354.69 lacs compared to Rs. 376.35 lacs in the year-ago quarter, a modest ~6% decline YoY. Reported EPS of Rs. 2.22 (vs Rs. 0.41) is not comparable because the equity base expanded following the company's recent IPO listing on NSE and BSE on September 3, 2025. The auditor (RVD & Co.) issued an unmodified review report with no qualifications.
Weak top-line performance with a double-digit YoY revenue decline and slightly lower profits may weigh on near-term sentiment, though the clean audit and steady margins provide some comfort. With the company only recently listed, post-IPO disclosures should be watched for broader business clarity and order book trends.